L-Asparaginase-Induced Complete Response in a Relapsed Patient with Epstein-Barr Virus and Cytotoxic Peripheral T-Cell Lymphoma Not Otherwise Specified

Tsutomu Takahashi; Fumiyoshi Ikejiri; Chie Onishi; Koshi Kawakami; Masaya Inoue; Takaaki Miyake; Junko Tanaka; Asuka Araki; Riruke Maruyama; Koichi Ohshima; Junji Suzumiya

doi:10.2169/internalmedicine.49.4083

CASE REPORTS

L-Asparaginase-Induced Complete Response in a Relapsed Patient with Epstein-Barr Virus and Cytotoxic Peripheral T-Cell Lymphoma Not Otherwise Specified

Tsutomu Takahashi, Fumiyoshi Ikejiri, Chie Onishi, Koshi Kawakami, Masaya Inoue, Takaaki Miyake, Junko Tanaka, Asuka Araki, Riruke Maruyama, Koichi Ohshima, Junji Suzumiya

Author information

Tsutomu Takahashi
Department of Hematology, Shimane University Hospital
Fumiyoshi Ikejiri
Department of Hematology, Shimane University Hospital
Chie Onishi
Department of Hematology, Shimane University Hospital
Koshi Kawakami
Department of Hematology, Shimane University Hospital
Masaya Inoue
Cancer Center, Shimane University Hospital
Takaaki Miyake
Department of Hematology, Shimane University Hospital
Junko Tanaka
Department of Hematology, Shimane University Hospital
Asuka Araki
Department of Pathology, Shimane University Hospital
Riruke Maruyama
Department of Pathology, Shimane University Hospital
Koichi Ohshima
Department of Pathology, Kurume University
Junji Suzumiya
Cancer Center, Shimane University Hospital

Keywords: peripheral T-cell lymphoma-NOS, L-asparaginase, Epstein-Barr virus, cytotoxic molecule, hemophagocytic syndrome

JOURNAL OPEN ACCESS

2010 Volume 49 Issue 22 Pages 2505-2508

DOI https://doi.org/10.2169/internalmedicine.49.4083

Details

Abstract

We present a patient with Epstein-Barr virus (EBV)-positive cytotoxic peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) who was successfully treated using only L-asparaginase. A 46-year-old Japanese man was diagnosed with EBV-positive cytotoxic PTCL-NOS. Although he underwent chemotherapy using multiple agents, he relapsed with hemophagocytic syndrome. L-asparaginase treatment was initiated at 6,000 U/m² on days 1, 3, 5, 10, and 12 together with prednisolone at 1 mg/kg. Although he developed grade 2 liver dysfunction and grade 2 coagulopathy, the patient achieved complete response status. Finally, he underwent allogeneic bone marrow stem cell transplantation, and he is currently still alive without disease at 24 months after the start of L-asparaginase therapy.

Corresponding author

Register with J-STAGE for free!